Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Alibaba Shares Fall as AI Spending Hits Profit 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Trump Signs Order to Cut Routine Childhood Vaccines 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Add as a preferred source on Google
Hanmi Pharm shares surged 30% on Monday after the South Korean pharmaceutical company signed an exclusive licensing agreement with Genentech, a member of the Roche Group, for its experimental obesity drug HM17321.
Under the agreement, Genentech will receive exclusive worldwide rights to develop, manufacture and commercialize HM17321, excluding South Korea. Hanmi Pharm will receive an upfront payment of $190 million as part of the partnership.
The potential total value of the licensing deal could reach approximately $2.3 billion if certain development, regulatory and commercial milestones are achieved. Hanmi could also receive tiered royalties based on future sales of HM17321, according to a statement from the companies.
The agreement represents a significant opportunity for Hanmi Pharm as pharmaceutical companies race to develop new obesity treatments amid strong global demand for weight-loss therapies.
HM17321 is a UCN2, or urocortin-2, analog that uses a non-incretin mechanism of action. Unlike widely used GLP-1-based obesity treatments, the experimental therapy targets a different biological pathway.
Hanmi Pharm has described HM17321 as a potential first-in-class obesity treatment designed to support weight reduction while preserving lean body mass. Maintaining muscle during weight loss has become an important area of research as drugmakers work to improve the effectiveness and long-term benefits of obesity therapies.
Preclinical studies have shown that HM17321 can reduce weight when administered as a standalone treatment. The drug has also demonstrated weight-loss effects when combined with GLP-1-based therapies, potentially opening the door to combination treatment strategies.
The Genentech licensing agreement provides HM17321 with the backing of Roche's global drug development and commercialization network while allowing Hanmi Pharm to retain rights to the treatment in South Korea.
Investor enthusiasm over the deal sent Hanmi Pharm shares up 30%, reflecting expectations that HM17321 could become a significant contender in the rapidly expanding global obesity drug market.
